

Massimiliano Mirabella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6120032/publications.pdf>

Version: 2024-02-01

210
papers

7,357
citations

53794

45
h-index

74163

75
g-index

215
all docs

215
docs citations

215
times ranked

9680
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2022, 269, 1463-1469.	3.6	4
2	Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. <i>Neurotherapeutics</i> , 2022, 19, 325-333.	4.4	32
3	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. <i>Journal of Personalized Medicine</i> , 2022, 12, 36.	2.5	7
4	Hsa-miR223-3p circulating level is upregulated in Friedreich's ataxia and inversely associated with HCLS1 associated protein X-1, HAX-1. <i>Human Molecular Genetics</i> , 2022, , .	2.9	1
5	A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis. <i>IScience</i> , 2022, 25, 103763.	4.1	12
6	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	9
7	Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects. <i>Journal of Personalized Medicine</i> , 2022, 12, 549.	2.5	4
8	The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. <i>Journal of Personalized Medicine</i> , 2022, 12, 591.	2.5	0
9	Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?. <i>Frontiers in Neurology</i> , 2022, 13, 844873.	2.4	4
10	Shift of multiple sclerosis onset towards older age. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1137-1139.	1.9	12
11	Heterozygous <i>KIF1A</i> variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. <i>Journal of Medical Genetics</i> , 2021, 58, 475-483.	3.2	21
12	A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1941-1947.	1.9	3
13	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2238-2245.	3.6	15
14	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	3.6	18
15	Efficacy and Safety of Bimagrumb in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
16	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	4.4	24
17	Defining the disease course of TNF± blockers-associated Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2021, 353, 577525.	2.3	4
18	Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	4

#	ARTICLE	IF	CITATIONS
19	Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. <i>Cells</i> , 2021, 10, 1146.	4.1	23
20	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.6	9
21	The neurobiological underpinning of the social cognition impairments in patients with spinocerebellar ataxia type 2. <i>Cortex</i> , 2021, 138, 101-112.	2.4	22
22	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross-sectional study. <i>Brain and Behavior</i> , 2021, 11, e02151.	2.2	12
23	Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments. <i>Neurourology and Urodynamics</i> , 2021, 40, 1500-1508.	1.5	8
24	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. <i>CNS Drugs</i> , 2021, 35, 861-880.	5.9	29
25	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
26	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate. <i>Frontiers in Neurology</i> , 2021, 12, 683398.	2.4	5
27	Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. <i>Neurotherapeutics</i> , 2021, 18, 2598-2607.	4.4	12
28	F19...Cognitive reserve: the leisure time concurs to the cognition performance and to the independence of early huntington disease patients. , 2021, , .		0
29	Comment on: Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110500.	3.5	2
30	CSF CXCL13 and chitinase 3-like-1 concentrations predict disease course in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118114.	0.6	0
31	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	4.4	39
32	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	3.6	6
33	Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101450.	2.0	8
34	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. <i>Neurological Sciences</i> , 2020, 42, 2837-2845.	1.9	11
35	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	3.6	19
36	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. <i>Neurotherapeutics</i> , 2020, 17, 994-1004.	4.4	34

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2020, 40, 319-326.	2.2	5
38	Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1159-1161.	3.3	2
39	Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102323.	2.0	34
40	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 564.	2.4	30
41	Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102498.	5.8	32
42	Frataxin deficiency in Friedreichâ€™s ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. <i>Human Molecular Genetics</i> , 2020, 29, 471-482.	2.9	8
43	A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 3267-3273.	0.7	11
44	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. <i>Acta Myologica</i> , 2020, 39, 57-66.	1.5	24
45	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î² 1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101952.	2.0	0
46	Hereditary inclusion-body myopathies. , 2020, , 479-489.		0
47	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. <i>Annals of Neurology</i> , 2019, 85, 296-301.	5.3	28
48	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	10.2	91
49	The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 176-181.	2.0	13
50	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. <i>Frontiers in Neurology</i> , 2019, 10, 695.	2.4	5
51	A unique case of multiphasic ADEM or what else?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 73-75.	2.0	1
52	The influence of physiotherapy intervention on patients with multiple sclerosisâ€™related spasticity treated with nabiximols (THC:CBD oromucosal spray). <i>PLoS ONE</i> , 2019, 14, e0219670.	2.5	7
53	P.20Expanding the myasthenia-myositis association spectrum: clinical, morphological and immunological data form a large case series. <i>Neuromuscular Disorders</i> , 2019, 29, S47.	0.6	0
54	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. <i>Frontiers in Immunology</i> , 2019, 10, 1916.	4.8	39

#	ARTICLE	IF	CITATIONS
55	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116423.	0.6	6
56	A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. <i>Neurology</i> , 2019, 92, e2109-e2117.	1.1	40
57	Genome-Wide Multiple Sclerosis Association Data and Coagulation. <i>Frontiers in Neurology</i> , 2019, 10, 95.	2.4	7
58	Different regimen of natalizumab treatment in multiple sclerosis patients: A real world study in Italy. <i>Journal of the Neurological Sciences</i> , 2019, 405, 338-339.	0.6	1
59	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	1.9	59
60	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. <i>Clinical Neurology and Neurosurgery</i> , 2018, 168, 60-63.	1.4	9
61	The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. <i>Neuroepidemiology</i> , 2018, 50, 105-110.	2.3	4
62	Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort. <i>Journal of Neurology</i> , 2018, 265, 542-551.	3.6	36
63	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , 2018, 391, 1263-1273.	13.7	684
64	Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 910-918.	3.0	5
65	Systematic assessment and characterization of chronic pain in multiple sclerosis patients. <i>Neurological Sciences</i> , 2018, 39, 445-453.	1.9	39
66	Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1366-1374.	3.0	51
67	Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. <i>Current Opinion in Immunology</i> , 2018, 55, 89-96.	5.5	45
68	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2018, 324, 165-171.	2.3	10
69	BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression. <i>PLoS ONE</i> , 2018, 13, e0206140.	2.5	24
70	Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1272-1278.	1.9	10
71	The cerebellar topography of attention sub-components in spinocerebellar ataxia type 2. <i>Cortex</i> , 2018, 108, 35-49.	2.4	14
72	Potential Effect of Cyclophosphamide on Bleb Survival in Five Patients with Multiple Sclerosis Who Underwent Glaucoma Surgery. <i>Ophthalmology and Therapy</i> , 2018, 7, 431-436.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018, 32, 963-970.	5.9	35
74	Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. <i>Brain and Behavior</i> , 2018, 8, e00968.	2.2	24
75	Fingolimod vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2018, 91, e153-e161.	1.1	35
76	Altered intestinal permeability in patients with relapsingâ€“remitting multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 442-446.	3.0	107
77	Response to the letter to the Editor for the manuscript â€œSleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort studyâ€“by Tomoyuki Kawada. <i>Journal of the Neurological Sciences</i> , 2017, 373, 142.	0.6	0
78	Association study reveals novel risk loci for sporadic inclusion body myositis. <i>European Journal of Neurology</i> , 2017, 24, 572-577.	3.3	11
79	Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 372, 33-39.	0.6	30
80	A phase 3 randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of sialic acid extended-release tablets in patients with GNE myopathy (GNEM). <i>Neuromuscular Disorders</i> , 2017, 27, S150.	0.6	0
81	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. <i>Neuroepidemiology</i> , 2017, 48, 171-178.	2.3	6
82	SativexÂ® effects on promoter methylation and on CNR1 / CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2017, 379, 298-303.	0.6	11
83	Prevalence and severity of liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. <i>Journal of Hepatology</i> , 2017, 66, S399-S400.	3.7	0
84	Novel <i>SEC61G</i> / <i>EGFR</i> Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens. <i>Cancer Research</i> , 2017, 77, 5860-5872.	0.9	21
85	PLEC gene mutations cause familial disto-proximal myopathy and long QT syndrome mimicking mitochondrial disease. <i>Neuromuscular Disorders</i> , 2017, 27, S150-S151.	0.6	1
86	Sporadic inclusion body myositis: A polygenic disorder?. <i>Neuromuscular Disorders</i> , 2017, 27, S155.	0.6	0
87	Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study. <i>Journal of the Neurological Sciences</i> , 2017, 372, 387-392.	0.6	37
88	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 284-294.	3.6	44
89	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). <i>PLoS ONE</i> , 2017, 12, e0180651.	2.5	24
90	Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception. <i>European Journal of Neurology</i> , 2016, 23, 630-640.	3.3	14

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	1.9	88
92	Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. <i>Journal of Molecular Neuroscience</i> , 2016, 59, 18-23.	2.3	104
93	Huntington's disease and suicidal behavior: The importance of lithium treatment. <i>Clinical Neurology and Neurosurgery</i> , 2016, 145, 108-109.	1.4	5
94	Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 11-13.	2.0	4
95	D6â€¦Dna damage in lymphocytes as a predictor of illness evolution in pre-manifest and overt huntingtonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.3-A36.	1.9	0
96	Riluzole in patients with hereditary cerebellar ataxia â€“ Authors' reply. <i>Lancet Neurology, The</i> , 2016, 15, 789.	10.2	5
97	Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 68-69.	2.0	6
98	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. <i>Journal of Neurology</i> , 2016, 263, 751-759.	3.6	35
99	An atypical case of acute disseminated encephalomyelitis associated with cytomegalovirus infection. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 70-72.	2.0	4
100	Effects of rehabilitation treatment of the upper limb in multiple sclerosis patients and predictive value of neurophysiological measures. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2016, 52, 819-826.	2.2	2
101	Blepharoptosis onset after topical prostaglandin therapy for glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 689-690.	2.6	1
102	Idiopathic inflammatory myopathies evaluated by near-infrared spectroscopy. <i>Muscle and Nerve</i> , 2015, 51, 830-837.	2.2	3
103	Hereditary Inclusion-Body Myopathies. , 2015, , 1145-1152.		0
104	Analyzing the Effects of a G137V Mutation in the FXN Gene. <i>Frontiers in Molecular Neuroscience</i> , 2015, 8, 66.	2.9	14
105	IFN-Î² Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 668-681.	1.2	10
106	Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. <i>European Neurology</i> , 2015, 73, 57-65.	1.4	20
107	Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e5-2005.e13.	3.1	42
108	Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features. <i>Clinical Neurophysiology</i> , 2015, 126, 2406-2408.	1.5	12

#	ARTICLE	IF	CITATIONS
109	Acyclovir-related kidney injury during alemtuzumab infusion. <i>Journal of Neurology</i> , 2015, 262, 1772-1774.	3.6	2
110	Epstein-Barr virus genetic variants are associated with multiple sclerosis. <i>Neurology</i> , 2015, 84, 1362-1368.	1.1	44
111	Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. <i>Muscle and Nerve</i> , 2015, 52, 956-962.	2.2	93
112	A Case of Hemiabdominal Myoclonus. <i>Clinical EEG and Neuroscience</i> , 2015, 46, 331-334.	1.7	2
113	Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 985-991.	10.2	163
114	Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. <i>Neurological Sciences</i> , 2015, 36, 2301-2302.	1.9	7
115	Hereditary inclusion-body myopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 644-650.	3.8	33
116	A shared haplotype for dentatorubropallidoluysian atrophy (DRPLA) in Italian families testifies of the recent introduction of the mutation. <i>Journal of Human Genetics</i> , 2014, 59, 153-157.	2.3	6
117	Case of postpartum Parsonage-Turner syndrome. <i>Muscle and Nerve</i> , 2014, 49, 294-295.	2.2	2
118	Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved. <i>JAMA Neurology</i> , 2014, 71, 924.	9.0	2
119	Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. <i>Autoimmunity Highlights</i> , 2014, 5, 77-85.	3.9	63
120	Rasmussen encephalitis: an unusual cause for intractable seizures in elderly. <i>Neurological Sciences</i> , 2014, 35, 143-145.	1.9	4
121	Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies. <i>Clinical Neurophysiology</i> , 2014, 125, 1925-1926.	1.5	1
122	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?. <i>Lancet Neurology</i> , The, 2014, 13, 864.	10.2	3
123	Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. <i>Journal of Neurology</i> , 2013, 260, 2396-2402.	3.6	44
124	Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion. <i>NeuroImmunoModulation</i> , 2013, 20, 341-347.	1.8	26
125	Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. <i>Journal of Neuroimmunology</i> , 2013, 263, 155-158.	2.3	49
126	Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 265, 124-127.	2.3	27

#	ARTICLE	IF	CITATIONS
127	Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. <i>Clinical Neurophysiology</i> , 2013, 124, 1615-1621.	1.5	13
128	Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2013, 22, 4748-4755.	2.9	94
129	Bilateral thoracic long nerve involvement in motor multifocal neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 584-584.	1.9	1
130	Atrophy, Fibrosis, and Increased PAX7-Positive Cells in Pharyngeal Muscles of Oculopharyngeal Muscular Dystrophy Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 234-243.	1.7	47
131	TWEAK in Inclusion-Body Myositis Muscle. <i>American Journal of Pathology</i> , 2012, 180, 1603-1613.	3.8	30
132	Multi-organ investigation in 16 CADASIL families from central Italy sharing the same R1006C mutation. <i>Neuroscience Letters</i> , 2012, 506, 116-120.	2.1	8
133	Intravascular large B-cell lymphoma presenting as slowly progressive paraparesis with normal MRI features. <i>Journal of the Neurological Sciences</i> , 2012, 314, 171-174.	0.6	4
134	Different Molecular Signatures in Magnetic Resonance Imaging-Staged Facioscapulohumeral Muscular Dystrophy Muscles. <i>PLoS ONE</i> , 2012, 7, e38779.	2.5	106
135	Muscle imaging findings in GNE myopathy. <i>Journal of Neurology</i> , 2012, 259, 1358-1365.	3.6	57
136	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1220-1230.	3.8	211
137	Muscle MRI in female carriers of dystrophinopathy. <i>European Journal of Neurology</i> , 2012, 19, 1256-1260.	3.3	31
138	Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. <i>Neuromuscular Disorders</i> , 2011, 21, 194-203.	0.6	16
139	Mesoangioblasts from Facioscapulohumeral Muscular Dystrophy Display in Vivo a Variable Myogenic Ability Predictable by their in Vitro Behavior. <i>Cell Transplantation</i> , 2011, 20, 1299-1313.	2.5	26
140	CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI. <i>Journal of Clinical Immunology</i> , 2011, 31, 155-166.	3.8	113
141	Mixed connective tissue disease presenting as a peculiar myositis with poor muscle regeneration. <i>Neurological Sciences</i> , 2011, 32, 171-174.	1.9	4
142	Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. <i>Neurological Sciences</i> , 2011, 32, 841-847.	1.9	33
143	Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. <i>Neurological Sciences</i> , 2010, 31, 79-81.	1.9	6
144	Analysis of NCAM helps identify unusual phenotypes of hereditary inclusion-body myopathy. <i>Neurology</i> , 2010, 75, 265-272.	1.1	28

#	ARTICLE	IF	CITATIONS
145	Increased aging in primary muscle cultures of sporadic inclusion-body myositis. <i>Neurobiology of Aging</i> , 2010, 31, 1205-1214.	3.1	35
146	An Italian case of hereditary myopathy with early respiratory failure (HMERF) not associated with the titin kinase domain R279W mutation. <i>Neuromuscular Disorders</i> , 2010, 20, 730-734.	0.6	15
147	Vessel-associated stem cells from skeletal muscle: From biology to future uses in cell therapy. <i>World Journal of Stem Cells</i> , 2010, 2, 39.	2.8	15
148	T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. <i>Clinical Immunology</i> , 2009, 131, 70-83.	3.2	21
149	Hereditary inclusion-body myopathy: Clues on pathogenesis and possible therapy. <i>Muscle and Nerve</i> , 2009, 40, 340-349.	2.2	26
150	Regulatory T cells fail to suppress CD4 ⁺ T-bet ⁺ T cells in relapsing multiple sclerosis patients. <i>Immunology</i> , 2009, 127, 418-428.	4.4	78
151	Progressive multifocal leukoencephalopathy in a patient with Franklin disease and hypogammaglobulinemia. <i>Journal of the Neurological Sciences</i> , 2009, 284, 203-204.	0.6	9
152	An Italian family with inclusion-body myopathy and frontotemporal dementia due to mutation in the <i>VCP</i> gene. <i>Muscle and Nerve</i> , 2008, 37, 111-114.	2.2	44
153	Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle. <i>Journal of Neurochemistry</i> , 2008, 105, 971-981.	3.9	53
154	The persistency of high levels of pSTAT3 expression in circulating CD4 ⁺ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 205, 126-134.	2.3	22
155	IL17 and IFN γ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. <i>Cytokine</i> , 2008, 44, 22-25.	3.2	53
156	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. <i>Human Immunology</i> , 2008, 69, 837-839.	2.4	27
157	The ER-Bound RING Finger Protein 5 (RNF5/RMA1) Causes Degenerative Myopathy in Transgenic Mice and Is Deregulated in Inclusion Body Myositis. <i>PLoS ONE</i> , 2008, 3, e1609.	2.5	57
158	Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy. <i>Neurology</i> , 2007, 68, 161-162.	1.1	27
159	Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. <i>FASEB Journal</i> , 2007, 21, 1210-1226.	0.5	209
160	A human anti-neuronal autoantibody against GABAB receptor induces experimental autoimmune agrypnia. <i>Experimental Neurology</i> , 2007, 204, 808-818.	4.1	20
161	Isolation and Characterization of Mesoangioblasts from Facioscapulohumeral Muscular Dystrophy Muscle Biopsies. <i>Stem Cells</i> , 2007, 25, 3173-3182.	3.2	37
162	Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. <i>Clinical Immunology</i> , 2007, 124, 284-293.	3.2	25

#	ARTICLE	IF	CITATIONS
163	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 192, 174-183.	2.3	74
164	Brainstem signs with progressing atrophy of medulla oblongata and upper cervical spinal cord. <i>Lancet Neurology</i> , The, 2007, 6, 562-570.	10.2	21
165	Integrated Backscatter in Becker Muscular Dystrophy Patients With Functionally Normal Heart: Myocardial Ultrasound Tissue Characterization Study. <i>Journal of the American College of Cardiology</i> , 2006, 47, 686-688.	2.8	9
166	Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. <i>Clinical Immunology</i> , 2006, 118, 77-82.	3.2	58
167	Skeletal muscle apoptosis is not increased in gastric cancer patients with mild to moderate weight loss. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 1561-1570.	2.8	18
168	Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. <i>Neuromuscular Disorders</i> , 2006, 16, 93-98.	0.6	64
169	Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. <i>Journal of Neurochemistry</i> , 2006, 96, 777-789.	3.9	35
170	Coeliac disease presenting with acute disseminated encephalomyelitis. <i>European Journal of Neurology</i> , 2006, 13, 202-203.	3.3	6
171	pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. <i>Journal of Neuroscience Research</i> , 2006, 84, 1027-1036.	2.9	129
172	In vivo Effects of Mitoxantrone on the Production of Pro- and Anti-Inflammatory Cytokines by Peripheral Blood Mononuclear Cells of Secondary Progressive Multiple Sclerosis Patients. <i>NeuroImmunoModulation</i> , 2006, 13, 76-81.	1.8	5
173	NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. <i>Neurology</i> , 2006, 66, 755-758.	1.1	66
174	MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16995-17000.	7.1	75
175	Neurotrophic Factors and Clinical Recovery in Relapsing-Remitting Multiple Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2005, 62, 176-182.	2.7	77
176	Clinical characteristics, course and prognosis of spinal multiple sclerosis. <i>Spinal Cord</i> , 2005, 43, 731-734.	1.9	22
177	Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy. <i>Disease Markers</i> , 2005, 21, 49-55.	1.3	23
178	Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. <i>Peptides</i> , 2005, 26, 2289-2293.	2.4	17
179	Î±-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy. <i>Neuromuscular Disorders</i> , 2005, 15, 177-184.	0.6	39
180	Insulin-like Growth Factor I in Inclusion-Body Myositis and Human Muscle Cultures. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 650-659.	1.7	19

#	ARTICLE	IF	CITATIONS
181	Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients. <i>Journal of Clinical Immunology</i> , 2004, 24, 287-293.	3.8	30
182	Constitutive activation of MAPK cascade in acute quadriplegic myopathy. <i>Annals of Neurology</i> , 2004, 55, 195-206.	5.3	114
183	Novel GNE mutations in Italian families with autosomal recessive hereditary inclusion-body myopathy. <i>Human Mutation</i> , 2004, 23, 632-632.	2.5	52
184	Pilot trial of phenylbutyrate in spinal muscular atrophy. <i>Neuromuscular Disorders</i> , 2004, 14, 130-135.	0.6	128
185	Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. <i>Journal of Neuroimmunology</i> , 2003, 139, 150-154.	2.3	94
186	Pathogenic role of mtDNA duplications in mitochondrial diseases associated with mtDNA deletions. <i>American Journal of Medical Genetics Part A</i> , 2003, 118A, 247-254.	2.4	15
187	Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 309-316.	2.8	65
188	Enhanced Dystrophic Progression in mdx Mice by Exercise and Beneficial Effects of Taurine and Insulin-Like Growth Factor-1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 453-463.	2.5	179
189	Cervical cord dysfunction during neck flexion in Hirayama's disease. <i>Neurology</i> , 2003, 60, 1980-1983.	1.1	49
190	An Italian family with autosomal recessive inclusion-body myopathy and mutations in the <i>GNE</i> gene. <i>Neurology</i> , 2002, 59, 1808-1809.	1.1	27
191	Apoptosis and ROS Detoxification Enzymes Correlate with Cytochrome c Oxidase Deficiency in Mitochondrial Encephalomyopathies. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 696-705.	2.2	50
192	Relapsing-remitting autoimmune agrypnia. <i>Annals of Neurology</i> , 2001, 50, 668-671.	5.3	44
193	Deletion Polymorphism of DNASE1L1, an X-Linked DNase I-like Gene, in Acid Maltase Deficiency Disorders. <i>Experimental and Molecular Pathology</i> , 2001, 70, 173-174.	2.1	7
194	Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. <i>European Journal of Human Genetics</i> , 2001, 9, 113-120.	2.8	48
195	Coenzyme Q ₁₀ reverses pathological phenotype and reduces apoptosis in familial CoQ ₁₀ deficiency. <i>Neurology</i> , 2001, 57, 515-518.	1.1	157
196	An Italian family with autosomal recessive quadriceps-sparing inclusion-body myopathy (ARQS-IBM) linked to chromosome 9p1. <i>Neurological Sciences</i> , 2000, 21, 99-102.	1.9	10
197	Î³1- and Î³2-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 15851-15860.	3.4	117
198	Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. <i>Brain</i> , 2000, 123, 93-104.	7.6	117

#	ARTICLE	IF	CITATIONS
199	Apoptotic features accompany acute quadriplegic myopathy. <i>Neurology</i> , 2000, 55, 854-858.	1.1	58
200	Molecular Characterization of a Novel Endonuclease (Xib) and Possible Involvement in Lysosomal Glycogen Storage Disorders. <i>Experimental and Molecular Pathology</i> , 1999, 66, 123-130.	2.1	13
201	The drastic reduction of SMN protein in SMA I spinal cord motor neurons is not due to inefficient transcription. <i>Neurogenetics</i> , 1999, 2, 97-100.	1.4	2
202	Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. <i>Neurology</i> , 1998, 51, 592-595.	1.1	37
203	Difference in Expression of Phosphorylated Tau Epitopes between Sporadic Inclusion-body Myositis and Hereditary Inclusion-body Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 774-786.	1.7	96
204	Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. <i>Annals of Neurology</i> , 1996, 39, 389-391.	5.3	54
205	Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy. <i>Annals of Neurology</i> , 1996, 40, 264-264.	5.3	20
206	Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. <i>Annals of Neurology</i> , 1996, 40, 864-872.	5.3	37
207	Ophthalmoplegia, demyelinating neuropathy, leukoencephalopathy, myopathy, and gastrointestinal dysfunction with multiple deletions of mitochondrial DNA: A mitochondrial multisystem disorder in search of a name. <i>Muscle and Nerve</i> , 1994, 17, 667-674.	2.2	46
208	Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. <i>Lancet, The</i> , 1994, 343, 364-365.	13.7	44
209	Idiopathic inflammatory myopathies. <i>Current Opinion in Neurology</i> , 1994, 7, 448-456.	3.6	38
210	Manifesting heterozygotes in McArdle's disease: clinical, morphological and biochemical studies in a family. <i>Journal of the Neurological Sciences</i> , 1993, 115, 91-94.	0.6	24